Kenneth Bauer Columnista Experto de SIIC Associate Professor of Medicine, Harvard Medical School.Chief, Hematology Section, VA Boston Healthcare System. Director, Thrombosis Clinical Research, Beth Israel Deaconess Medical Center

EXPERIENCIA CLINICA CON FONDAPARINUX: UN NUEVO INHIBIDOR SINTETICO SELECTIVO DEL FACTOR XA Columnista Experto de SIIC Kenneth Bauer Fecha de aprobación: 21 de Octubre, 2003 Primera edición en siicsalud: 28 de Noviembre, 2003 Sección Artículos originales, subsección Expertos del Mundo, página http://www.siicsalud.com/des/des034/03n25002.htm   Especialidad principal: . Especialidades relacionadas:  Hematología,  Farmacología,  Medicina Farmacéutica,  Emergentología,  Cuidados Intensivos,  Medicina Interna. Bauer KA, Hawkins DW, Peters PC, Petitou M, Herbert J-M, van Boeckel CAA, Meuleman DG. Fondaparinux, a synthetic pentasaccharide: The first in a new class of antithrombotic agents - the selective factor Xa inhibitors Cardiovasc Drug Rev 20:37-52, 2002 Lassen MR, Bauer KA, Eriksson BI, Turpie AGG for the European Pentasaccharide Hip Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison Lancet 359:1715-1720, 2002 Turpie AGG, Bauer KA, Eriksson BI, Lassen MR for the PENTATHLON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison Lancet 359:1721-1726, 2002 Turpie AGG, Bauer KA, Eriksson BI, Lassen MR for the Steering Committees of the Pentasaccharide Orthopedic Prophylaxis Studies. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery. A meta-analysis of 4 randomized double-blind studies Arch Intern Med 162:1833-1840, 2002 Eriksson BI, Bauer KA, Lassen MR, Turpie AGG for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for preventing venous thromboembolism after hip-fracture surgery N Eng J Med 345:1298-1305, 2001 Bauer KA. The thrombophilias: Well-defined risk factors with uncertain therapeutic implications Ann Intern Med 135:367-373, 2001 Bauer KA, Eriksson BI, Lassen MR, Turpie AGG for the Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery N Eng J Med 345(1305-1310), 2001 Dr.  Kenneth Bauer Dirección profesional: Beth Israel Deaconess Medical Center. 330 Brookline Avenue, Boston, Massachussets 02215, EE.UU.

Bienvenidos a siicsalud
Acerca de SIIC] [Estructura de SIIC]

Sociedad Iberoamericana de Información Científica (SIIC)
Av. Belgrano 430, (C1092AAR), Buenos Aires, Argentina
atencionallector@siicsalud.com; Tel: +54 11 4342-4901; Fax: +54 11 4331-3305.
Casilla de Correo 2568, (C1000WAZ)  Correo Central, Buenos Aires.
Copyright siicsalud© 1997- 2006, Sociedad Iberoamericana de Información Científica (SIIC)